NC
KALV

nVerses Capital’s KalVista Pharmaceuticals KALV Stock Holding History

nVerses Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$2.32K – 444
2024
Q3 		$2.32K Sell
200
-1,900
-90% -$23.9K ﹤0.01% 951
2024
Q2 		$24.7K Buy
+2,100
New +$24.5K 0.01% 747

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

nVerses Capital's KALV Position: Q4 2024 in Review

nVerses Capital sold out of KalVista Pharmaceuticals (KALV) in Q4 2024, closing a stake of 200 shares — an estimated $2.32K sold.

nVerses Capital first reported a position in KALV in Q2 2024 and held it in 2 quarters. The position peaked at $24.7K in Q2 2024. 130 funds tracked by Wall St. Rank hold KALV as of Q4 2024.

  • nVerses Capital reported no remaining KalVista Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 200 KalVista Pharmaceuticals shares in Q4 2024, an estimated $2.32K.
  • nVerses Capital first reported a position in KalVista Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • nVerses Capital's KalVista Pharmaceuticals position peaked at $24.7K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.